Exendin-4
Ex-4, exendin(1-39); the synthetic copy is exenatide (Byetta, Bydureon, Bydureon BCise)
1What it is
Exendin-4 is a real animal venom peptide that became a mainstream diabetes drug. In 1992 John Eng, working at a Veterans Affairs hospital in the Bronx, isolated it from the venom of the Gila monster, a slow desert lizard of the south-western United States and Mexico. He was following up on the observation that Gila monster venom caused pancreatic effects in experimental animals.
The peptide shares roughly half its sequence with human GLP-1, enough to activate the same receptor. Crucially, position 2 of exendin-4 is glycine rather than alanine, which makes it resistant to dipeptidyl peptidase-4 (DPP-4), the enzyme that chews up human GLP-1 within about two minutes. A lizard that eats a few times a year had evolved a long-acting version of a human hormone.
Synthetic exendin-4 was developed as exenatide and approved in the United States in 2005 — the first GLP-1 receptor on the market, the compound that opened the entire drug class that now includes semaglutide (profile #3) and tirzepatide. Exenatide itself has since been largely displaced by weekly agents with better efficacy and tolerability, and the brands have been discontinued in a number of countries.
Note on naming: "exendin-4" and "exenatide" are the same 39-amino-acid sequence. Exendin-3 is a related peptide from the beaded lizard. Exendin(9-39) is a fragment that acts as a GLP-1 receptor blocker and is used as a research antagonist — the opposite pharmacology, and a common source of confusion.
2How it's thought to work
3What the research shows
Type 2 diabetes glycaemic control
Cardiovascular outcomes
Weight
Parkinson's disease
GLP-1 receptor imaging
Other explored uses
4Reported side effects and interactions
Literature-reported
Common (literature). nausea (around 40–50% in the twice-daily trials, higher than most newer agents), vomiting, diarrhoea, constipation, headache, injection-site nodules (particularly common with the extended-release microsphere formulation, where firm lumps could persist for weeks).
Serious / warnings. acute pancreatitis — exenatide carried post-marketing reports and a label warning; acute kidney injury and worsening renal function, including cases associated with dehydration from vomiting (exenatide is renally cleared and was contraindicated below eGFR 30); gallbladder disease; hypersensitivity reactions including rare anaphylaxis; the extended-release product carried a boxed warning for thyroid C-cell tumours seen in rodents, of unknown human relevance. Antibodies to exenatide developed in a substantial minority of patients and in a small subset were associated with loss of glycaemic response.
Hypoglycaemia. uncommon with exenatide alone but clearly increased in combination with a sulfonylurea; label advised reducing the sulfonylurea dose.
Grey-market considerations. because the brands are discontinued in several markets, "exendin-4" now circulates as a bulk research peptide. The documented risks for this class of unlicensed product are unit-confusion dosing errors, incorrect salt forms, and contamination. No bulk research peptide has been shown equivalent to the licensed product.
Interactions. delayed gastric emptying slows absorption of oral medicines — the label advised taking antibiotics and oral contraceptives at least one hour before injection; warfarin INR monitoring on initiation; additive hypoglycaemia with insulin and sulfonylureas.
Markers researchers commonly monitor
Taken from the approved-label monitoring and the trial protocols:
| Marker | Why it's watched |
|---|---|
| HbA1c and fasting glucose | the primary measure of effect, and the main thing the trials were powered on. |
| eGFR and creatinine | exenatide is renally cleared, was contraindicated in severe impairment, and had post-marketing acute kidney injury reports, usually with vomiting and dehydration. |
| Lipase and amylase | checked if significant abdominal pain develops, given the pancreatitis signal. |
| Weight and waist circumference | the secondary endpoint across the programme. |
| Blood pressure and resting heart rate | the class raises heart rate by a few beats per minute. |
| Anti-drug antibodies | not a routine clinical test, but the mechanism behind loss of response in a minority of trial participants, and worth knowing about if effect fades. |
| Injection sites | the extended-release formulation produced palpable nodules; rotation and inspection were standard trial practice. |
Free for everyone. Safety information is never behind a paywall.
5Reconstitution and handling
The approved products required no — Byetta was a pre-filled multidose pen delivering fixed 5 µg or 10 µg doses; the weekly product was a single-use autoinjector or vial-and-syringe kit requiring vigorous mixing of the microsphere suspension immediately before injection. bulk exendin-4 requires reconstitution and careful unit arithmetic: label doses are in micrograms, and confusion between micrograms, milligrams and "units" is the single most commonly reported error with this class.
Open in calculator, pre-loaded →6Commonly studied alongside
Semaglutide (#3) and tirzepatide as successor agents and trial comparators; metformin, sulfonylureas and insulin (the approved combinations); exendin(9-39) as the matching receptor antagonist in mechanism studies.
Informational cross-links. Not stack recommendations.
7Regulatory status by region
| Region | Status (checked —) |
|---|---|
| United States | Exenatide was FDA-approved (Byetta 2005; Bydureon 2012; Bydureon BCise 2017). Byetta and the Bydureon products have been discontinued by the manufacturer; generic exenatide availability varies † |
| European Union | Exenatide was EMA-authorised (Byetta, Bydureon); marketing has been discontinued † |
| United Kingdom | Was MHRA-licensed, prescription-only; discontinued in line with the EU position † |
| Australia | Was TGA-registered; availability discontinued † |
| South Africa | Was SAHPRA-registered; current availability uncertain † |
| Sport | GLP-1 receptor agonists are not prohibited by WADA as of 2026 † |
8Open questions
- Why did exenatide fail to show cardiovascular benefit when semaglutide and liraglutide succeeded — pharmacokinetics, exposure, or trial design?
- Does any GLP-1 modify Parkinson's disease, given the Phase 2/Phase 3 discordance?
- What accounts for the far greater weight effect of newer agents at comparable receptor engagement?
9References
- 1Eng J et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. PubMed
- 2DeFronzo RA et al. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. PubMed · DOI
- 3Buse JB et al. (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. PubMed · DOI
- 4Drucker DJ et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1). Lancet. PubMed
- 5Holman RR et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). NEJM. PubMed · DOI
- 6Athauda D et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. PubMed · DOI
- 7AstraZeneca. Byetta and Bydureon BCise prescribing information (most recent label). PubMed
References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.
† Being confirmed by our reviewers against current sources.
10Community
Threads and protocols are visible to members. Joining is free.
Self-reported side effects Phase 2
11Page history
Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.